Preclinical and translational validation were performed using additional mosunetuzumab preclinical data and blinatumomab clinical data in r/r ALL, providing confidence in the predictive capabilities of the model for different B-cell targets (CD19 vs. CD20), species (cyno vs. human), drug format and PK (BiTE vs. full-length antibody), and B-cell malignancies (ALL and DLBCL). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.